The bounce that began on Friday gains momentum as idle cash looks for a place to go. Stock-picking and rotation are key themes.
In late August/early September the major indices were making medium-term tops.
Obstacles that lie ahead, but this market never seems to embrace a negative narrative for long.
The result has been a technical breakdown in risk-asset pricing -- and the main culprit is without a doubt, the inability of Congress to compromise.
Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.
For investors seeking value, growth and income potential - and to sleep better at night - the utility space warrants attention.
The greedy are, at last, getting blown out, and the prudent being vindicated. I see three buckets of stocks that intrigue me now.
That doesn't mean there aren't good picks to be found. You just have to look harder.
There is only one fact that truly needs to be understood. The virus is still in charge until it is not.
The big-cap technology names are still more extended than much of the rest of the market.